BeiGene, Ltd/$ONC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BeiGene, Ltd
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Ticker
$ONC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Basel, Switzerland
Employees
11,000
ISIN
US07725L1026
Website
BeiGene, Ltd Metrics
BasicAdvanced
$29B
-
-$3.70
0.30
-
Price and volume
Market cap
$29B
Beta
0.3
52-week high
$287.88
52-week low
$174.74
Average daily volume
335K
Financial strength
Current ratio
1.964
Quick ratio
1.645
Long term debt to equity
6.145
Total debt to equity
28.485
Interest coverage (TTM)
-15.99%
Profitability
EBITDA (TTM)
-122.006
Gross margin (TTM)
84.81%
Net profit margin (TTM)
-9.40%
Operating margin (TTM)
-7.10%
Effective tax rate (TTM)
-46.04%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-3.22%
Return on equity (TTM)
-11.44%
Valuation
Price to revenue (TTM)
6.12
Price to book
7.44
Price to tangible book (TTM)
7.55
Price to free cash flow (TTM)
-106.274
Free cash flow yield (TTM)
-0.94%
Free cash flow per share (TTM)
-226.96%
Growth
Revenue change (TTM)
51.16%
Earnings per share change (TTM)
-51.11%
3-year revenue growth (CAGR)
68.23%
10-year revenue growth (CAGR)
79.79%
3-year earnings per share growth (CAGR)
-43.48%
10-year earnings per share growth (CAGR)
1.21%
Bulls say / Bears say
BeiGene's stock reached a 52-week high of $258.66, reflecting robust revenue growth of 50.22% and a gross profit margin of 83.67%, indicating strong financial health and investor confidence. (Investing.com)
The European Commission approved BeiGene's TEVIMBRA for first-line treatment of advanced esophageal and gastric cancers, potentially expanding the company's market share in oncology. (Business Wire)
Analysts from Morgan Stanley and Jefferies have reiterated 'Buy' ratings for BeiGene, with price targets of $317 and $286 respectively, suggesting strong future performance expectations. (TipRanks)
InvestingPro analysis indicates that BeiGene's stock may be overvalued at current levels, with technical indicators suggesting overbought conditions, which could lead to a price correction. (Investing.com)
A significant increase in short interest for BeiGene's stock suggests that some investors are betting on a decline in the company's share price. (MarketBeat)
Despite recent approvals, BeiGene faces intense competition in the oncology market, which could impact its market share and profitability. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
BeiGene, Ltd News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BeiGene, Ltd stock?
BeiGene, Ltd (ONC) has a market cap of $29B as of June 30, 2025.
What is the P/E ratio for BeiGene, Ltd stock?
The price to earnings (P/E) ratio for BeiGene, Ltd (ONC) stock is 0 as of June 30, 2025.
Does BeiGene, Ltd stock pay dividends?
No, BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next BeiGene, Ltd dividend payment date?
BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders.
What is the beta indicator for BeiGene, Ltd?
BeiGene, Ltd (ONC) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.